We are live on ! Find out more

Sutro Biopharma

STRO

Market cap $152M

9.14 USD

-0.15

1.61%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

9.14

0.00

0%

1 day

-1.61%

5 days

-10.57%

1 month

-43.23%

3 months

-60.81%

6 months

-74.17%

Year to date

-16.61%

1 year

-12.95%

5 years

-95.47%

10 years

-93.99%

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Employees: 128

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 75%

Negative 25%

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

— STRO-006 is Sutro's second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a range of solid tumors.

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026.

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.

Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next-generation integrin 6 (ITGB6)-targeting ADC, is on track to enter the clinic in the third quarter of 2026 – – Second dual-payload iADC program from Sutro's platform under Astellas collaboration expected to enter the clinic in the second half of 2026 – – Strong balance sheet with $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to support operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the second quarter ended June 30, 2026 and recent business highlights.

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 – – First dual-payload iADC from Sutro's platform entered the clinic under Astellas collaboration; patient dosing underway – – Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2026 and recent business highlights.

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

Zacks Investment Research

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026

Sutro Biopharma is an early-stage ADC developer, trading at a $406m market cap after a strong 6-month rally. STRO's pipeline centers on next-generation ADCs, with lead candidate STRO-004 in Phase 1 and key data expected mid-2026. Strategic partnerships, notably with Astellas, offer milestone potential, but past alliances (Ipsen, BMY, EMD Serono) have lapsed.

Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

Sutro Biopharma to Participate in Upcoming Investor Conferences

Zacks Investment Research

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

See News Rankings

Price charts implemented using Lightweight Charts™